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Over the past decade substantial advances have been made in understanding the biological and 
molecular mechanisms of chronic lymphocytic 
leukaemia (CLL). The evaluation of new 
chemotherapeutic combinations has led to an 
increase in the rate of complete remission in patients 
with CLL. In addition, the use of monoclonal 
antibodies such as rituximab and alemtuzumab 
has added substantial benefit when combined 
with chemotherapy.1,2 However, the ability to 
eradicate disease at a molecular level, and improve 
clinically relevant patient outcome measures, 
continue to pose difficult challenges. Regardless of 
the stage of the disease, most patients will relapse 
after initial treatment and become refractory to 
salvage chemotherapy with median overall survival 
ranging from 10 to 19 months.3,4 Thus, the need 
to develop alternative therapies to kill leukaemic 
cells, or to fight relapse, remains a hot topic 
under intense investigation. Targeting cell-surface 
molecules present on leukaemic B-cells with T-cells 
transfected with chimeric antigen receptors (CAR) 
may be an attractive immunotherapeutic strategy to 
reduce the leukaemic cell burden.
CAR can be engineered by combining an 
antigen-specific monoclonal antibody using its 
variable chain fragments with a T-cell activating 
signalling receptor in a single fusion protein.5 Once 
this modified protein is expressed on the surface 
of a T-cell, and binds to its specific antigen, an 
activation signal is transmitted into the T-cell. This 
latter will trigger its effector functions to lyse the 
target cell. Typically, T-cells expressing CAR react 
like conventional T-cells, but attach to the target 
antigen  by the variable chain fragments of the 
monoclonal antibody, and so are named T-bodies. 
Since its first description, CAR design has 
evolved over the years with the goal of enhancing 
T-cell signalling functions [Figure 1]. The first 
generation of CAR consisted of heavy and light chain 
immunoglobulin variable regions fused in a single 
chain and coupled to signalling modules, which are 
normally present in the T-cell receptor complex 
such as the CD3zeta-chain.6 This first generation 
of CAR effectively redirected T-cell cytotoxicity, 
but failed to enable T-cell proliferation and survival 
upon repeated antigen exposure, and anti-tumour 
responses were limited.7 The second generation of 
CAR incorporated another signalling receptor from 
co-stimulatory molecules such as CD28, CD134 
or CD137 to reduce activation-induced cell death 
and improve T-cell survival. The third generation of 
CAR incorporated two co-stimulatory molecules: 
CD28, CD134 or CD137 in a sequence fused to 
CD3-zeta chain and were designed to further 
enhance killing functions, proliferation capacities 
and production of survival cytokines such as 
interleukin-2.7,8 Compared to classical T-cell-based 
immunotherapies, T-cells expressing-CAR present 
several attractive advantages including obviating the 
need for recognising peptide presentation by major 
histocompatibility complex, the ability to target 
a range of tumour surface antigens, and relatively 
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rapid generation within one to four weeks.5,7,8
Although the clinical value of genetically 
engineered T-cells is still to be validated, recent 
data from two studies reported that CAR targeting 
CD19 (CART19) was able to kill leukaemic B-cells 
expressing this surface antigen and that tumour 
control was sustained for 10 months following this 
therapy.9,10 The CART19 was designed to express 
a single chain variable fragment derived from an 
anti-CD19 specific antibody along with a CD137 
signalling domain and the CD3zeta-chain. T-cells 
expressing-CART19 were generated by transfecting 
autologous T-cells from each CLL patient with 
a lentiviral vector, which express the CART19 
construct. Prior to receiving a low dose of CART19, 
patients received lymphodepleting chemotherapy 
with pentostatin and cyclophosphamide and, 4 
days later, 1.42 x 107 of engineered CART19 cells 
were administrated without additional cytokines or 
monoclonal antibodies. Two to three weeks after 
CART19 immunotherapy, patients developed a 
tumour lysis syndrome, which correlated positively 
with an increase in the number of circulating 
T-cells expressing CART19. Three to four days 
later the tumour lysis syndrome subsided without 
evidence of disease on physical examination. There 
was no palpable adenopathy and no evidence of 
CLL in the bone marrow. In addition, computed 
tomography (CT) scans showed a resolution 
of adenopathies. Six to 10 months following 
CART19 infusion, two of three subjects showed 
a complete remission with no residual CLL found 
by means of physical examination, CT scans, flow-
cytometry and cytogenetic analyses. Normal B cells 
however continued to be lacking. Of note, each 
infused CART19 cell eradicated on average about 
1,000 malignant cells. T-cell expressing CART19 
underwent robust expansion, persisted at high 
levels in both circulating blood and bone marrow 
for at least 6 months and, most importantly, a 
proportion of these T-cells expressed memory 
markers and retained anti-CD19 effector functions. 
As expected the most frequent side effects, in 
addition to the tumour lysis syndrome, were B-cell 
lymphopenia and hypogammaglobulinaemia but 
these undesirable conditions should be manageable 
in CLL patients.
Overall, these small pilot, prospective, single-
centre studies yielded very encouraging results as 
two of the three patients enrolled in the clinical trial 
had p53 gene deletion, which predicts poor survival, 
non-response to therapy and rapid progression. 
It also provides a proof of principle that CAR 
represents a promising approach to treat CLL 
patients and possibly other B-cell malignancies.11,12 
Indeed, this therapy resulted in partial remission 
Figure 1: Simplified representation of chimeric antigen receptors (CAR) design. Generally, T-cells expressing-CAR 
consist of a single chain variable fragments (scFv) from a monoclonal antibody, a transmembrane region (TM) and 
signaling receptors such as CD3zeta-chain domain (first generation), two signaling domains (second generation) 
or three signaling domains (third generation).
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in a patient with follicular lymphoma for up to 
32 weeks.11 In a more recent study, three patients 
with bulky CLL and one patient with B-cell acute 
lymphoblastic exhibited a response to CART19 
containing CD28 as a co-stimulatory molecule 12.
Accordingly, CART19 is generating substantial 
enthusiasm and its clinical value will probably 
be evaluated in large clinical trials. However, one 
potential concern is that co-stimulatory signals 
may lead to uncontrolled CAR T-cell proliferation 
thereby increasing the long term risk of toxicity by 
depleting non-tumour cells, which are important 
for homeostatic functions. It remains to be seen 
whether the long term side effects of CART19 will 
be acceptable or not. Another major safety issue is 
the theoretical risk of inducing oncogenic mutations 
after DNA integration of the vector. Previous 
reports have shown the occurrence of T-cell acute 
lymphoblastic leukaemia in four children treated 
with gene-transfer stem cells to correct their 
X-linked severe combined immunodeficiency.13 
However, in contrast to haematopoietic stem cells, 
retroviral vector integration to mature T-cells has 
been found to be a safe strategy as demonstrated 
by long-term engraftment of donor lymphocytes 
genetically engineered with the suicide gene 
thymidine kinase of herpes simplex virus after 
allogeneic stem cell transplantation.14,15 Treatment 
with CART19 is an innovative immunotherapeutic 
approach to target leukaemic B-cells in patients 
with advanced chemotherapy-resistant CLL.
Certainly, this approach is still in its infancy for 
clinical use, but it constitutes a new weapon against 
B-cell neoplasms and potentially a model to further 
improve the curative potential of cellular therapies 
in patients for whom conventional therapies have 
failed.
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